Huntington’s disease is marked by progressive neuroanatomical changes, assumed to underlie the development of the disease’s characteristic symptoms. Previous work has demonstrated longitudinal macrostructural white-matter atrophy, with some evidence of microstructural change focused in the corpus callosum.
Objective:
To more accurately characterise longitudinal patterns, we examined white matter microstructural change using Diffusion Tensor Imaging (DTI) data from three timepoints over a 15 month period.
Methods:
In 48 early-stage HD patients and 36 controls from the multi-site PADDINGTON project, diffusion tensor imaging (DTI) was employed to measure changes in fractional anisotropy (FA) and axial (AD) and radial diffusivity (RD) in 24 white matter regions-of-interest (ROIs).
Results:
Cross-sectional analysis indicated widespread baseline between-group differences, with significantly decreased FA and increased AD and RD found in HD patients across multiple ROIs. Longitudinal rates of change differed significantly between HD patients and controls in the genu and body of corpus callosum, corona radiata and anterior limb of internal capsule. Change in RD in the body of the corpus callosum was significantly associated with baseline disease burden, but other clinical associations were not significant.
Conclusions:
We detected subtle longitudinal white matter changes in early HD patients. Progressive white matter abnormalities in HD may not be uniform throughout the brain, with some areas remaining static in the early symptomatic phase. Longer assessment periods across disease stages will help map this progressive trajectory.
The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. 1993;72(6):971–83.
2.
RosasHD, KoroshetzWJ, ChenYI, SkeuseC, VangelM, CudkowiczME, et al. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology. 2003;60(10):1615–20.
3.
TabriziSJ, LangbehnDR, LeavittBR, RoosRA, DurrA, CraufurdD, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791–801.
4.
AylwardEH, CodoriAM, RosenblattA, SherrM, BrandtJ, StineOC, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov Disord. 2000;15(3):552–60.
5.
Georgiou-KaristianisN, GrayMA, DominguezDJ, DymowskiAR, BohannaI, JohnstonLA, et al. Automated differentiation of pre-diagnosis Huntington’s disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: The IMAGE-HD study. Neurobiol Dis. 2013;51:82–92.
6.
Georgiou-KaristianisN, ScahillR, TabriziSJ, SquitieriF, AylwardE. Structural MRI in Huntington’s disease and recommendations for its potential use in clinical trials. Neurosci Biobehav Rev. 2013;37(3):480–90.
7.
BohannaI, Georgiou-KaristianisN, SritharanA, AsadiH, JohnstonL, ChurchyardA, et al. Diffusion Tensor Imaging in Huntington’s disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav. 2011;5(3):171–80.
8.
Della NaveR, GinestroniA, TessaC, GiannelliM, PiacentiniS, FilippiM, et al. Regional distribution and clinical correlates of white matter structural damage in Huntington disease: A tract-based spatial statistics study. Am J Neuroradiol. 2010;31(9):1675–81.
9.
DelmaireC, DumasEM, SharmanMA, van den BogaardSJ, ValabregueR, JauffretC, et al. The structural correlates of functional deficits in early huntington’s disease. Hum Brain Ma. 2013;34(9):2141–53.
10.
DouaudG, BehrensTE, PouponC, CointepasY, JbabdiS, GauraV, et al. In vivo evidence for the selective subcortical degeneration in Huntington’s disease. Neuroimage. 2009;46(4):958–66.
11.
HobbsNZ, ColeJH, FarmerRE, ReesEM, CrawfordHE, MaloneIB, et al. Evaluation of multi-modal, multi-site neuroimaging measures in Huntington’s disease: Baseline results from the PADDINGTON study. Neuroimage Clin. 2013;2(1):204–11.
12.
KlöppelS, DraganskiB, GoldingCV, ChuC, NagyZ, CookPA, et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington’s disease. Brain. 2008;131(1):196–204.
13.
MagnottaVA, KimJ, KoscikT, BeglingerLJ, EspinsoD, LangbehnD, et al. Diffusion Tensor Imaging in Preclinical Huntington’s Disease. Brain Imaging Behav. 2009;3(1):77–84.
14.
MatsuiJT, VaidyaJG, JohnsonHJ, MagnottaVA, LongJD, MillsJA, et al. Diffusion weighted imaging of prefrontal cortex in prodromal huntington’s disease. Hum Brain Ma. 2014;35(4):1562–73.
15.
ReadingSAJ, YassaMA, BakkerA, DziornyAC, GourleyLM, YallapragadaV, et al. Regional white matter change in pre-symptomatic Huntington’s disease: A diffusion tensor imaging study. Psychiatry Res. 2005;140(1):55–62.
16.
Rizk-JacksonA, StoffersD, SheldonS, KupermanJ, DaleA, GoldsteinJ, et al. Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington’s disease using machine learning techniques. Neuroimage. 2011;56(2):788–96.
17.
StoffersD, SheldonS, KupermanJM, GoldsteinJ, Corey-BloomJ, AronAR. Contrasting gray and white matter changes in preclinical Huntington disease: An MRI study. Neurology. 2010;74(15):1208–16.
18.
Di PaolaM, LudersE, CherubiniA, Sanchez-CastanedaC, ThompsonPM, TogaAW, et al. Multimodal MRI analysis of the corpus callosum reveals white matter differences in presymptomatic and early Huntington’s disease. Cereb Cortex. 2012;22(12):2858–66.
19.
Di PaolaM, PhillipsOR, Sanchez-CastanedaC, Di PardoA, MaglioneV, CaltagironeC, et al. MRI measures of corpus callosum iron and myelin in early Huntington’s disease. Hum Brain Ma. 2014;35(7):3143–51.
20.
DumasEM, van den BogaardSJ, RuberME, ReilmanRR, StoutJC, CraufurdD, et al. Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington’s disease. Hum Brain Ma. 2012;33(1):203–12.
21.
MascalchiM, LolliF, Della NaveR, TessaC, PetralliR, GavazziC, et al. Huntington disease: Volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology. 2004;232(3):867–73.
22.
MullerHP, GlaucheV, NovakMJ, Nguyen-ThanhT, UnrathA, LahiriN, et al. Stability of white matter changes related to Huntington’s disease in the presence of imaging noise: A DTI study. PLoS Curr. 2011;3:RRN1232.
23.
NovakMJU, SeunarineKK, GibbardCR, HobbsNZ, ScahillRI, ClarkCA, et al. White matter integrity in premanifest and early Huntington’s disease is related to caudate loss and disease progression. Cortex. 2014;52(1):98–112.
24.
PhillipsO, Sanchez-CastanedaC, ElifaniF, MaglioneV, Di PardoA, CaltagironeC, et al. Tractography of the corpus callosum in Huntington’s disease. PLoS One. 2013;8(9):e73280.
25.
PhillipsO, SquitieriF, Sanchez-CastanedaC, ElifaniF, CaltagironeC, SabatiniU, et al. Deep white matter in Huntington’s disease. PloS One. 2014;9(10):e109676.
26.
PoudelGR, StoutJC, Domínguez DJF, SalmonL, ChurchyardA, ChuaP, et al. White matter connectivity reflects clinical and cognitive status in Huntington’s disease. Neurobiol Dis. 2014;65:180–7.
27.
RosasHD, LeeSY, BenderAC, ZaletaAK, VangelM, YuP, et al. Altered white matter microstructure in the corpus callosum in Huntington’s disease: Implications for cortical “disconnection”. Neuroimage. 2010;49(4):2995–3004.
28.
RosasHD, TuchDS, HeveloneND, ZaletaAK, VangelM, HerschSM, et al. Diffusion tensor imaging in presymptomatic and early Huntington’s disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006;21(9):1317–25.
29.
PoudelGR, StoutJC, DominguezDJ, ChurchyardA, ChuaP, EganGF, et al. Longitudinal change in white matter microstructure in Huntington’s disease: The IMAGE-HD study. Neurobiol Dis. 2015;74:406–12.
30.
OdishOF, LeemansA, ReijntjesRH, van den BogaardSJ, DumasEM, WolterbeekR, et al. Microstructural brain abnormalities in Huntington’s disease: A two-year follow-uHum Brain Ma2015;36(6):2061–74.
31.
AylwardEH, NopoulosPC, RossCA, LangbehnDR, PiersonRK, MillsJA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2011;82(4):405–10.
32.
CiarmielloA, CannellaM, LastoriaS, SimonelliM, FratiL, RubinszteinDC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med. 2006;47(2):215–22.
33.
HobbsNZ, HenleySM, RidgwayGR, WildEJ, BarkerRA, ScahillRI, et al. The progression of regional atrophy in premanifest and early Huntington’s disease: A longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry. 2010;81(7):756–63.
34.
RosasHD, ReuterM, DorosG, LeeSY, TriggsT, MalarickK, et al. A tale of two factors: What determines the rate of progression in Huntington’s disease? A longitudinal MRI study. Mov Disord. 2011;26(9):1691–7.
35.
SquitieriF, CannellaM, SimonelliM, SassoneJ, MartinoT, VendittiE, et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington’s disease. CNS Neurosci Thera. 2009;15(1):1–11.
36.
TabriziSJ, ReilmannR, RoosRA, DurrA, LeavittB, OwenG, et al. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: Analysis of 24 month observational data. Lancet Neurol. 2012;11(1):42–53.
37.
TabriziSJ, ScahillRI, DurrA, RoosRA, LeavittBR, JonesR, et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: The 12-month longitudinal analysis. Lancet Neurol. 2011;10(1):31–42.
38.
TabriziSJ, ScahillRI, OwenG, DurrA, LeavittBR, RoosRA, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637–49.
39.
HobbsNZ, FarmerRE, ReesEM, ColeJH, HaiderS, MaloneIB, et al. Short-interval observational data to inform clinical trial design in Huntington’s disease. J Neurol Neurosurg Psychiatry. 2015;86(12):1291–8.
40.
BeaulieuC. The basis of anisotropic water diffusion in the nervous system - A technical review. NMR Biomed. 2002;15(7-8):435–55.
DomínguezDJF, EganGF, GrayMA, PoudelGR, ChurchyardA, ChuaP, et al. Multi-modal neuroimaging in premanifest and early Huntington’s disease: 18 month longitudinal data from the IMAGE-HD Study. PloS One. 2013;8(9):e74131.
43.
VandenbergheW, DemaerelP, DomR, MaesF. Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington’s disease. J Neurol. 2009;256(1):109–14.
44.
SmithSM, JenkinsonM, Johansen-BergH, RueckertD, NicholsTE, MackayCE, et al. Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006;31(4):1487–505.
SritharanA, EganGF, JohnstonL, HorneM, BradshawJL, BohannaI, et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington’s disease. J Neurol Neurosurg Psychiatry. 2010;81(3):257–62.
47.
Unified Huntington’s Disease Rating Scale: Reliability and consistency. Huntington Study Group. Mov Disord. 1996;11(2):136–42.
48.
OdishOF, CaeyenberghsK, HosseiniH, van den BogaardSJ, RoosRA, LeemansA. Dynamics of the connectome in Huntington’s disease: A longitudinal diffusion MRI study. Neuroimage Clin. 2015;9:32–43.
49.
ShoulsonI, FahnS. Huntington disease: Clinical care and evaluation. Neurology. 1979;29(1):1–3.
50.
MüllerHP, GrönG, SprengelmeyerR, KassubekJ, LudolphAC, HobbsN, et al. Evaluating multicenter DTI data in Huntington’s disease on site specific effects: An ex post facto approach. Neuroimage Clin. 2013;2(1):161–7.
51.
CookPA, BaiY, Nedjati-GilaniS, SeunarineKK, HallMG, ParkerGJ, et al., editors. Camino: Open-Source Diffusion-MRI Reconstruction and Processing. 14th Scientific Meeting of the International Society for Magnetic Resonance in Medicine; 2006; Seattle, WA, USA.
52.
ZhangH, YushkevichPA, AlexanderDC, GeeJC. Deformable registration of diffusion tensor MR images with explicit orientation optimization. Med Image Anal. 2006;10(5):764–85.
53.
ZhangH, AvantsBB, YushkevichPA, WooJH, WangS, McCluskeyLF, et al. High-dimensional spatial normalization of diffusion tensor images improves the detection of white matter differences: An example study using amyotrophic lateral sclerosis. IEEE Trans Med Imaging. 2007;26(11):1585–97.
54.
WangY, GuptaA, LiuZ, ZhangH, EscolarML, GilmoreJH, et al. DTI registration in atlas based fiber analysis of infantile Krabbe disease. Neuroimage. 2011;55(4):1577–86.
55.
MullerMJ, MazanekM, WeibrichC, DellaniPR, StoeterP, FellgiebelA. Distribution characteristics, reproducibility, and precision of region of interest-based hippocampal diffusion tensor imaging measures. AJNR Am J Neuroradiol. 2006;27(2):440–6.
56.
KeihaninejadS, ZhangH, RyanN, MaloneI, FrostC, CardosoM, et al. Longitudinal changes in fiber tract integrity in Alzheimer’s disease: A serial diffusion tensor imaging study. Alzheimers Dement. 2012;8(S4):30–1.
57.
LeeCE, DanielianLE, ThomassonD, BakerEH. Normal regional fractional anisotropy and apparent diffusion coefficient of the brain measured on a 3 T MR scanner. Neuroradiology. 2009;51(1):3–9.
58.
MoriS, OishiK, JiangH, JiangL, LiX, AkhterK, et al. Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage. 2008;40(2):570–82.
59.
ColeJH, FarmerRE, ReesEM, JohnsonHJ, FrostC, ScahillRI, et al. Test-Retest Reliability of Diffusion Tensor Imaging in Huntington’s Disease. PLoS Curr. 2014;6: pii: ecurrents.hd.f19ef63fff962f5cd9c0e88f4844f43b.
60.
OurselinS, RocheA, SubsolG, PennecX, AyacheN. Reconstructing a 3D structure from serial histological sections. Image Vis Comput. 2001;19(1-2):25–31.
61.
ModatM, RidgwayGR, TaylorZA, LehmannM, BarnesJ, HawkesDJ, et al. Fast free-form deformation using graphics processing units. Comput Methods Programs Biomed. 2010;98(3):278–84.
62.
BenjaminiY, HochbergY. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289–300.
63.
CrawfordHE, HobbsNZ, KeoghR, LangbehnDR, FrostC, JohnsonH, et al. Corpus callosal atrophy in premanifest and early Huntington’s disease. J Huntingtons Dis. 2013;2(4):517–26.
64.
JonesDK, KnoscheTR, TurnerR. White matter integrity, fiber count, and other fallacies: The do’s and don’ts of diffusion MRI. Neuroimage. 2013;73:239–54.
65.
SongSK, SunSW, JuWK, LinSJ, CrossAH, NeufeldAH. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage. 2003;20(3):1714–22.
66.
SunSW, LiangHF, CrossAH, SongSK. Evolving Wallerian degeneration after transient retinal ischemia in mice characterized by diffusion tensor imaging. Neuroimage. 2008;40(1):1–10.
67.
Van CampN, BlockxI, CamónL, De VeraN, VerhoyeM, VeraartJ, et al. A complementary diffusion tensor imaging (DTI)-histological study in a model of Huntington’s disease. Neurobiol Aging. 2012;33(5):945–59.
68.
SongSK, YoshinoJ, LeTQ, LinSJ, SunSW, CrossAH, et al. Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage. 2005;26(1):132–40.
69.
BuddeMD, XieM, CrossAH, SongSK. Axial diffusivity is the primary correlate of axonal injury in the experimental autoimmune encephalomyelitis spinal cord: A quantitative pixelwise analysis. J Neurosci. 2009;29(9):2805–13.
70.
ConchaL, GrossDW, WheatleyBM, BeaulieuC. Diffusion tensor imaging of time-dependent axonal and myelin degradation after corpus callosotomy in epilepsy patients. Neuroimage. 2006;32(3):1090–9.
71.
Della NaveR, GinestroniA, DiciottiS, SalvatoreE, SoricelliA, MascalchiM. Axial diffusivity is increased in the degenerating superior cerebellar peduncles of Friedreich’s ataxia. Neuroradiology. 2011;53(5):367–72.
72.
JensenJH, HelpernJA. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. NMR Biomed. 2010;23(7):698–710.
73.
ZhangH, SchneiderT, Wheeler-KingshottCA, AlexanderDC. NODDI: Practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage. 2012;61(4):1000–16.
74.
ZhangH, HubbardPL, ParkerGJM, AlexanderDC. Axon diameter mapping in the presence of orientation dispersion with diffusion MRI. Neuroimage. 2011;56(3):1301–15.
75.
AssafY, Blumenfeld-KatzirT, YovelY, BasserPJ. AxCaliber: A method for measuring axon diameter distribution from diffusion MRI. Magn Reson Med. 2008;59(6):1347–54.
PenneyJB, VonsattelJP, MacDonaldME, GusellaJF, MyersRH. CAG repeat number governs the development rate of pathology in huntington’s disease. Ann Neurol. 1997;41(5):689–92.
78.
PapadakisNG, XingD, HuangCL, HallLD, CarpenterTA. A comparative study of acquisition schemes for diffusion tensor imaging using MRI. J Magn Reson. 1999;137(1):67–82.
79.
JonesDK. The effect of gradient sampling schemes on measures derived from diffusion tensor MRI: A Monte Carlo study. Magn Reson Med. 2004;51(4):807–15.
Barrio-ArranzG, de Luis-GarciaR, Tristan-VegaA, Martin-FernandezM, Aja-FernandezS. Impact of MR Acquisition Parameters on DTI Scalar Indexes: A Tractography Based Approach. PloS One. 2015;10(10):e0137905.
82.
MullerHP, SussmuthSD, LandwehrmeyerGB, LudolphA, TabriziSJ, KloppelS, et al. Stability effects on results of diffusion tensor imaging analysis by reduction of the number of gradient directions due to motion artifacts: An application to presymptomatic Huntington’s disease. PLoS Curr. 2011;3:RRN1292.
